Abstracts Archive - Page 2198 of 2425 - ACR Meeting Abstracts

Abstract Number: 775 • 2013 ACR/ARHP Annual Meeting
Cytokine-Mediated Repression Of The Lncrna Hotair Enhances Intracellular Signaling and The Expression Of Adhesion Molecules In Synovial Fibroblasts
Michelle Trenkmann¹, Mojca Frank Bertoncelj¹, Matthias Brock², Christoph Kolling³, Renate E. Gay⁴, Beat A. Michel⁵, Diego Kyburz¹, Lars C. Huber² and Steffen Gay¹, ¹Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Zurich, Switzerland, ²Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland, ³Schultess Clinic, Zurich, Switzerland, ⁴Center of Experimental Rheumatology, Zurich University Hospital, Zurich, Switzerland, ⁵Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) synovial fibroblasts (SF) are characterized by a stably activated phenotype which is, at least in part, because of the epigenetic inheritance…
Abstract Number: 776 • 2013 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Modifies Chromatin Landscape and Amplifies Inflammatory Responses To Subsequent Stimuli In Synovial Fibroblasts
Angela Lee¹, Lionel B. Ivashkiv² and George D. Kalliolias¹, ¹Medicine, Hospital for Special Surgery, New York, NY, ²Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Fibroblast-like synoviocytes (FLS) cross-talk with macrophages (Mf) during the course of rheumatoid arthritis (RA). Our group has shown that TNFa, primarily Mf-derived within synovium,…
Abstract Number: 777 • 2013 ACR/ARHP Annual Meeting
A Unique Role For Galectin-9 In Angiogenesis and Inflammatory Arthritis
Martin O'Brien¹, Qiang Shu², Pei-Suen Tsou³, William Stinson⁴, Jeffrey H. Ruth³, Takeo Isozaki⁵, Alisa E. Koch⁶, David A. Fox⁵ and M. Asif Amin⁵, ¹Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ²Department of Internal Medicine, University of Michigan Medical School and Qilu Hospital of Shandong University, Ann Arbor, MI, ³Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁴Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁵Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ⁶VA Medical Service, Ann Arbor, MI
Background/Purpose: Galectin-9 (Gal-9) is a mammalian lectin which contributes to T-cell autoimmunity and tumor biology. Here, we examined the contribution of Gal-9 in angiogenesis and…
Abstract Number: 778 • 2013 ACR/ARHP Annual Meeting
Relationship of Meeting Physical Activity Guidelines and Quality Adjusted Life Years
Kai Sun¹, Jing Song², Larry Manheim³, C. Kent Kwoh⁴, Rowland W. Chang², Pamela A. Semanik⁵, Dorothy D. Dunlop² and Charles Eaton⁶, ¹Medicine, Northwestern University, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Institute Healthcare Studies, Northwestern University, Chicago, IL, ⁴School of Medicine, Department of Medicine, Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁵Northwestern University, Chicago, IL, ⁶Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI
Background/Purpose: Regular physical activity is associated with reduced chronic disease burden and mortality. Recognizing the importance of physical activity, there are US federal guidelines for…
Abstract Number: 779 • 2013 ACR/ARHP Annual Meeting
Low Cardiovascular Mortality Among Early Rheumatoid Arthritis Patients — A Nationwide Register Study 2000—2008
Anne M. Kerola¹, Tuomo Nieminen², Lauri J. Virta³, Hannu Kautiainen⁴, Kari Puolakka⁵, Tuomas Kerola⁶, Timo Pohjolainen⁷ and Markku J. Kauppi⁶, ¹Medical School, University of Helsinki, Helsinki, Finland, ²Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ³Research Department, the Social Insurance Institution, Turku, Finland, ⁴Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, ⁵Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ⁶Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁷ORTON Rehabilitation Centre, ORTON Foundation, Helsinki, Finland
Background/Purpose: Increased cardiovascular (CV) mortality in established rheumatoid arthritis (RA) is a widely accepted threat, but in early RA or inception cohorts, growing evidence suggests…
Abstract Number: 780 • 2013 ACR/ARHP Annual Meeting
Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants
Candace H. Feldman¹, Linda T. Hiraki², Francisco M. Marty³, Wolfgang C. Winkelmayer⁴, Jessica M. Franklin⁵, Daniel H. Solomon^6,7, Seoyoung C. Kim⁸ and Karen H. Costenbader⁹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ³Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ⁴Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are among the leading causes of hospitalization and mortality in patients with systemic lupus erythematosus (SLE); approximately 50% have a serious infection during…
Abstract Number: 781 • 2013 ACR/ARHP Annual Meeting
Mortality Rates, Readmissions and Revascularisation Following a First Myocardial Infarction In Patients With Autoimmune Rheumatic Disease Compared With Controls
Sharon Van Doornum^1,2, Megan Bohensky¹, Mark Tacey¹, Caroline Brand^1,3, Vijaya Sundararajan⁴ and Ian Wicks⁵, ¹Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, ²Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ³Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia, ⁴Medicine, University of Melbourne, Melbourne, Australia, ⁵Rheumatology Unit, Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: We have previously demonstrated increased case fatality following myocardial infarction (MI) in rheumatoid arthritis (RA) patients[1], however post-MI case fatality has not been investigated…
Abstract Number: 782 • 2013 ACR/ARHP Annual Meeting
Rates Of Malignancies In Patients From 5 Rheumatoid Arthritis Registries Across The World
Johan Askling¹, Niklas Berglind², Stefan Franzén², Thomas Frisell³, Christopher Garwood⁴, Jeffrey D. Greenberg⁵, Meilien Ho⁶, Marie Holmqvist¹, Laura Horne⁷, Kathy Lampl⁸, Kaleb Michaud⁹, Fredrik Nyberg¹⁰, Dimitrios A. Pappas¹¹, George Reed¹², Eiichi Tanaka¹³, Trung Tran¹⁴, Suzanne Verstappen⁴, Hisashi Yamanaka¹⁵ and Deborah Symmons⁴, ¹Karolinska Institutet, Stockholm, Sweden, ²AstraZeneca R&D Mölndal, Mölndal, Sweden, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁷AstraZeneca, Wilmington, DE, ⁸AstraZeneca R&D Wilmington, Wilmington, DE, ⁹University of Nebraska Medical Center and National Data Bank, Omaha, NE, ¹⁰AstraZeneca R&D, Mölndal, Sweden, ¹¹Columbia University, New York, NY, ¹²University of Massachusetts Medical School, Worcester, MA, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The overall incidence of cancer in patients with rheumatoid arthritis (RA) is modestly elevated compared with the general population. The extent to which cancer…
Abstract Number: 783 • 2013 ACR/ARHP Annual Meeting
Outcome In Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death
Stefan Kleinert¹, Margret Breunig², Hans-Peter Tony³, Martin Feuchtenberger⁴, Marc Schmalzing⁵, Christian Kneitz⁶, Stefanie Lehmann⁷, Christiane Angermann^7,8, Georg Ertl⁸ and Stefan Störk⁷, ¹Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, ²Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Wuerzburg, Germany, ³Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ⁶Internal Medicine II, Hospital Südstadt, Rostock, Germany, ⁷Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany, ⁸Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Patients with rheumatoid disease (RD) have an increased mortality risk compared to the normal population, mainly due to cardiovascular (CV) disease. Only a proportion…
Abstract Number: 784 • 2013 ACR/ARHP Annual Meeting
IgG4+ Plasmablasts Are A Novel Biomarker In IgG4-Related Disease
Mollie Carruthers¹, Hamid Mattoo², Zachary S. Wallace³, Vinay Mahajan⁴, Shiv Pillai⁵ and John H. Stone¹, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁴Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Oncology, Massachusetts General Hospital, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated disorder that responds to B cell depletion with rituximab (RTX). We detected IgG4+ plasmablasts in the sera of…
Abstract Number: 785 • 2013 ACR/ARHP Annual Meeting
Ophthalmic Manifestations Of IgG4-Related Disease: A Single-Center Experience
Zachary S. Wallace¹, Vikram Deshpande² and John H. Stone³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Pathology, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is an inflammatory disorder responsible for fibrosing, tumefactive lesions that can present in nearly any anatomic location. The orbital manifestations of…
Abstract Number: 786 • 2013 ACR/ARHP Annual Meeting
Antibodies Against Drp-4 and Macropain Subunit C2 As a Potential Marker Of Aosd
Niklas T. Baerlecken¹, Nils Pursche², Torsten Witte³, Reinhold E. Schmidt¹, Marius Hoepfner¹, Frank Moosig⁴, Wolfgang L. Gross⁵, Eugen Feist⁶ and Dirk Foell⁷, ¹Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, ²Clinical Immunology and Rheumatology, Medical University of Hannover, Hannover, Germany, ³Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ⁴Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ⁵Dept of Clinical Rheumatology, Medical University at Lubeck, Lubeck, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁷Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Making the diagnosis of adult-onset Still's disease (AOSD) is mainly based on the exclusion of inflammatory, infectious and malignant diseases. There are no specific…
Abstract Number: 787 • 2013 ACR/ARHP Annual Meeting
Serum Leucine-Rich Alpha-2 Glycoprotein As a Marker For Disease Activity In Adult-Onset Still’s Disease
You-Jung Ha¹, Jung-Soo Song², Eun-Jin Kang³, Sang-Won Lee⁴, Yong-Beom Park⁴, Soo-Kon Lee⁴ and Sang Tae Choi², ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Leucine-rich a2-glycoprotein (LRG) is a plasma protein which contains leucine-rich repeats. Though physiological functions of LRG have not been clarified yet, it has been…
Abstract Number: 767 • 2013 ACR/ARHP Annual Meeting
Zinc Finger Protein ZCCHC6 Is Highly Expressed In Osteoarthritic Cartilage and Regulate The Expression Of Interleukin-6 In Human Chondrocytes
Nahid Akhtar, Ahmad Arida and Tariq M. Haqqi, Anatomy & Neurobiology, North East Ohio Medical University, Rootstown, OH
Background/Purpose: Interleukin-1β (IL-1β) is the major cytokine involved in cartilage catabolism in osteoarthritis(OA) and induces the expression of pro-inflammatory cytokine IL-6. Members of cytoplasmic RNA…
Abstract Number: 748 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice
Megan L. Krause¹, Misbah Baqir², Rodrigo Cartin-Ceba³, Tobias Peikert⁴, Karina Keogh⁴ and Ulrich Specks⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pulmonary/Critical Care, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Methotrexate has been shown to be effective for both induction (non-severe disease) and maintenance of remission in patients with Granulomatosis with Polyangiitis (GPA) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].